Tetra Bio-Pharma (GRPOF) Pioneers a New, Ancient Approach to Cannabinoid Delivery
November 14th, 2016
News, Top News
The vast majority of patients smoke medical marijuana rather than using edibles or pills. In fact, Canada only recently legalized non-smokable forms of medical marijuana under the ACMPR program. Although smoking may have a negative connotation due to tobacco’s reputation for causing lung cancer, smoked marijuana provides some very real benefits to patients relative to edibles, pills, and other modern delivery mechanisms.
In this article, we will take a look at how Tetra Bio-Pharma Inc. (OTC: GRPOF) (CSE: TBP) is bringing smokable, natural medical marijuana to market along with a number of other products targeting chronic pain, insomnia, PTSD, anxiety, and other conditions.
Smoking vs. Edibles
Marijuana-infused edibles have become a popular way to consume THC and CBDs without smoking the dried plant, but there are some key differences in the way that the drug is metabolized that could impact its medicinal value.
The liver metabolizes edible THC, producing an active metabolite that is very effective at crossing the blood-brain barrier where it eventually produces a ‘high’ feeling. By contrast, inhaled THC bypasses the liver and stomach and travels directly to the brain where it produces a faster high that diminishes more quickly. Inhaled cannabis also leads to higher concentrations of THC in the blood, which tends to be roughly 50-60% compared to just 10-20% for edibles.
These dynamics are important to consider from a medical perspective. The delay between the ingestion of edible THC and the onset of the ‘high’ effects could lead to overconsumption among patients. Individual differences in metabolism also make it difficult to come up with specific dosing and instructions applicable to everyone. By comparison, the instantaneous effects of inhaled cannabis enables patients to adjust their dosing as needed.
Several studies have also shown that cannabis smokers don’t have higher rates of lung cancer – a key concern among doctors prescribing these treatments. For example, one study looked at 2,159 lung cancer cases and 2,985 controls from six case-control studies across the U.S., Canada, the UK, and New Zealand. The results provided little evidence for an increased risk of lung cancer among habitual or long-term cannabis smokers.
Securing the Evidence
Tetra Bio-Pharma wants to prove that smokable medical marijuana has a place in healthcare by conducting rigorous clinical studies. While GW Pharmaceuticals plc (NASDAQ: GWPH) and others have secured approval for cannabis derivatives, nobody has proven to regulators that smokable cannabis has any medical benefits, which is why it remains a Schedule I Controlled Substance in the United States and illegal in other countries.
The company believes that its smokable medical marijuana would provide patients with a better natural alternative to synthesized chemical concoctions being developed by other companies in the space. With so many patients already using smokable medical marijuana, the company also has access to a wide patient population where it can draw data to support its clinical studies and ultimately secure regulatory approvals.
In addition to smokable marijuana, the company is pursuing a number of other clinical programs designed to leverage the botanical rather than a synthetic. Its PPP002 program is a Phase III botanical drug that is targeting insomnia in chronic pain patients, while its PPP003 is a combination oral product designed to treat chronic pain, PTSD, and neurological conditions – and it would compete with GW Pharma’s proprietary extracts.
Product to Market
Tetra Bio-Pharma has three divisions that management believes will be necessary to bring products to market, including an R&D arm, manufacturing arm, and sourcing arm. In combination with each other, the company is focusing on advancing a pipeline of six therapeutics, targeting a wide range of conditions. These markets are worth several billions of dollars per year and affect more than 1.5 billion people around the world.
The company’s three divisions include:
- Phyto Pain Pharma – A clinical-stage research and development firm focused on the development of pharmaceutical products containing plant-based cannabinoids.
- Agro Tek Health – A manufacturing and distribution company focused on acquiring, manufacturing, and distributing natural health products.
- Grow Pros Cannabis – A natural products company focused on cultivating and sourcing cannabis and industrial hemp and developing over-the-counter products. Tetra was formerly known as Grow Pros Cannabis Ventures.
The company’s clinical pipeline includes:
In a recent investor presentation, the company indicated that it would file for patent protection and file a pre-IND meeting with the FDA during Q4’16. The company would then provide an update on its topical drug trial, PPP002 trial, and its FDA meeting in Q1’17. The goal would be to have products through clinical trials in the beginning of 2018 before launching them.
Tetra Bio-Pharma is a biopharmaceutical cannabis company taking a unique approach to the medical cannabis market by advancing smokable marijuana products. In addition, the company is developing botanical solutions with the goal of reaching into the biopharmaceutical market, which experts believe will reach $291 billion in size by 2021. Investors may want to take a closer look given the unique focus and numerous upcoming catalysts.
For more information, visit the company’s website at www.tetrabiopharma.com.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.